A first-of-a-kind study has found that the pharmacokinetics of technosphere insulin operates the same way in adults and children living with type 1 diabetes.
During the study, the research team examined how the inhaled dry powder ultra-rapid-acting insulin affects children living with the condition.
Nearly 30 children with type 1 diabetes took part in the single-arm investigation, which analysed how pharmacokinetics of technosphere insulin impacted circulating glucose concentrations.
Each participant met pre-defined pulmonary function testing criteria and they all were on a stable multiple daily insulin injection regimen.
To assess pharmacokinetics, the children received an individualised single preprandial dose of technosphere insulin (4–12 U, in 4-U increments) via oral inhalation, based on their usual mealtime subcutaneously injected rapid-acting insulin dose and meal content. Serum insulin and blood glucose were also measured at 30 to 250 min relative to dosing.
The results conclude: “Serum insulin rapidly increased post-dose and returned to baseline by 120 min.
“Mean serum insulin Cmax (maximum concentration) was 77.3, 119.15, and 207.7 µU/mL for doses of 4, 8, and 12 U, respectively.
“Tmax occurred at 10.5, 13.9, and 14.6 min post-dose for 4, 8, and 12 U. Glucose lowering 30–60 min post-dose was consistent with the pharmacokinetics profile.”
The research is available here.
Photo by jonas mohamadi on Pexels